Atlas Trials

SABR Combined With Axitinib and Toripalimab for Oligometastatic Renal Cell Carcinoma

Clinical trial NCT07744932 · RECRUITING

Trial details

NCT number
NCT07744932
Sponsor
Hebei Medical University Fourth Hospital
Status
RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Oligometastatic Clear Cell Renal Cell Carcinoma
Start date
2026-08-15
Primary completion
2027-12-30
Enrollment
48

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.